IHVR-17028 is a potent broad-spectrum ERα-glucosidase I (α-glucosidase? I) inhibitor with IC50 of 0.24 μM and antiviral activity. IHVR-17028 inhibited BVDV, TCRV and DENV, and EC50 values were 0.4 μM, 0.26 μM and 0.3 μM, respectively. IHVR-17028 can be used to study infectious diseases.

DENV:0.3 μM, BVDV:0.4 μM, TCRV:0.26 μM, ERα-glucosidase I:0.24 μM

IHVR-17028 demonstrates potent antiviral activity against bovine viral diarrhea virus (BVDV) (NADL strain), tacaribe virus (TCRV) (11573 strain), and DENV (serotype 2, New Guinea C) with EC50 values of 0.4 μM, 0.26 μM, and 0.3 μM, respectively, in virus yield reduction assays. Furthermore, IHVR-17028 exhibits high cell viability with IC50 values exceeding 500 μM in MDBK, Huh7.5, and BHK cells, as determined by MTT assays.[1]

In rats, during pharmacokinetic analysis, IHVR17028 (75 mg/kg, oral gavage) demonstrates a C max value of 0.18 μg/ml. The T max value is 1.56 hours, and after PO administration, the F% value is 12%. The T 1/2 value is 0.88 hours after iv administration[1].
In a mouse model of lethal MARV infection, IHVR-17028 treatment (25-50 mg/kg, oral gavage) one day before virus challenging exhibits significant protection.[1]